SMARCA1 and cancer: Despite our current findings about the toxicity of the GSK-J4 compound in SMARCA4def cells, the effects could be broader, and cancer cells in which other members of the SWI/SNF-complex or of related pathways are genetically inactivated, may also be vulnerable to this inhibitor.